The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Multiple Genetic Alterations Cause Frequent and Heterogeneous Human Histocompatibility Leukocyte Antigen Class I Loss in Cervical Cancer
Open accessAbstract
The nature and frequency of human histocompatibility leukocyte antigen (HLA) class I loss mechanisms in primary cancers are largely unknown. We used flow cytometry and molecular analyses to concurrently assess allele-specific HLA phenotypes and genotypes in subpopulations from 30 freshly isolated cervical tumor cell suspensions. Tumor-associated HLA class I alterations were present in 90% of the lesions tested, comprising four altered pheno/genotype categories: (a) HLA-A or -B allelic loss (17%), mostly associated with gene mutations; (b) HLA haplotype loss, associated with loss of heterozygosity at 6p (50%). This category included cases with additional loss of a (third) HLA-A or -B allele due to mutation, as well as one case with an HLA class I–negative tumor cell subpopulation, caused by a β2-microglobulin gene mutation; (c) Total HLA class I antigen loss and retention of heterozygosity (ROH) at 6p (10%); and (d) B locus or HLA-A/B downregulation associated with ROH and/or allelic imbalance at 6p (10%). Normal HLA phenotypes and ROH at 6p were observed in 10% of the cases. One case could not be classified (3%). Altered HLA class I antigen expression occurs in most cervical cancers, is diverse, and is mainly caused by genetic changes. Combined with widespread tumor heterogeneity, these changes have profound implications for natural immunity and T cell–based immunotherapy in cervical cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The multistep nature of cancer
Vogelstein, B., & Kinzler, K. W. (1993) · Trends in Genetics · doi:10.1016/0168-9525(93)90209-z · Cited by 1,853
Marchand, M., van Baren, N., Weynants, P., Brichard, V., Dr�no, B., Tessier, M.-H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., et al. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>3.0.co;2-s · Cited by 784
Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
Garrido, F., Ruiz-Cabello, F., Cabrera, T., Pérez-Villar, J. J., López-Botet, M., Duggan-Keen, M., & Stern, P. L. (1997) · Immunology Today · doi:10.1016/s0167-5699(96)10075-x · Cited by 770
Ferrone, S., & Marincola, F. M. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80033-6 · Cited by 474
Cromme, F. V., Airey, J., Heemels, M. T., Ploegh, H. L., Keating, P. J., Stern, P. L., Meijer, C. J., & Walboomers, J. M. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.1.335 · Cited by 330
Seliger, B. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01052-9 · Cited by 215
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.
Hicklin, D. J., Wang, Z., Arienti, F., Rivoltini, L., Parmiani, G., & Ferrone, S. (1998) · Journal of Clinical Investigation · doi:10.1172/jci498 · Cited by 198
IGF-I and IGF-II in relation to colorectal cancer
Manousos, O. N., Souglakos, J., Bosetti, C., Τζώνου, Α., Chatzidakis, V., Trichopoulos, D., Adami, H., & Mantzoros, C. S. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990924)83:1<91::aid-ijc17>3.0.co;2-4 · Cited by 190
Loss of MHC class‐I expression in cervical carcinomas
Connor, M. E., & Stern, P. L. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910460614 · Cited by 188
Allelotype analysis of cervical carcinoma.
Mitra, A., Murty, V. V. V. S., Li, R. G., Pratap, M., Luthra, U. K., & CHAGANTI, R. S. K. (1994) · PubMed · Cited by 182
Cited by
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Does the Immune System See Tumors as Foreign or Self?
Pardoll, D. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141135 · Cited by 753
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
Mechanisms of Immune Evasion by Tumors
Drake, C. G., Jaffee, E., & Pardoll, D. M. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90002-9 · Cited by 688
The urgent need to recover MHC class I in cancers for effective immunotherapy
Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585
Metadata
- Authors
- Koopman, L. A., Corver, W. E., van der Slik, A. R., Giphart, M. J., & Fleuren, G. J.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2000-03-13
- Volume
- 191
- Issue
- 6
- Pages
- 961-976
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2152596295
- Cited by
- 279
- References
- 46
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multiple Genetic Alterations Cause Frequent and Heterogeneous Human Histocompatibility Leukocyte Antigen Class I Loss in Cervical Cancer. https://app.cochat.ai/papers/10.1084/jem.191.6.961
- The paper
- Koopman, L. A., Corver, W. E., van der Slik, A. R., Giphart, M. J., & Fleuren, G. J. (2000). Multiple Genetic Alterations Cause Frequent and Heterogeneous Human Histocompatibility Leukocyte Antigen Class I Loss in Cervical Cancer. The Journal of Experimental Medicine. https://doi.org/10.1084/jem.191.6.961
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.